RECRUITING

Effectiveness of Virtual Reality Vision Therapy - VERVE

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this research study is to see how well the treatment of a participant's eye coordination and/or focusing problems improves eye muscle responses and symptoms of eyestrain. We will use an entertainment device called a virtual reality headset to play a custom-designed video game to find out how well the treatment of binocular vision improves a participant's coordination and/or focusing problem. The virtual reality headset uses eye-trackers to monitor progress in a totally objective manner. Objective testing allows the doctor to determine the results without relying on a participant's ability to answer questions or respond verbally in any way. We will compare the results of a participant before and after playing the video game.

Official Title

Effectiveness of Vision Therapy in a Virtual Reality Headset

Quick Facts

Study Start:2021-10-14
Study Completion:2024-09
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04691427

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:9 Years to 35 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:CHILD, ADULT
Inclusion CriteriaExclusion Criteria
  1. * Age 9 years and older
  2. * CISS score ≥ 16
  3. * Best-corrected distance visual acuity of 20/25 or better in each eye
  4. * Random dot stereopsis appreciation of 500 seconds of arc or better
  5. * Parent or subject understands the protocol and is willing to enroll in the study
  1. * Constant strabismus at distance or near
  2. * Vertical heterophoria ≥ 2 ∆ at distance or near
  3. * ≥ 2 line interocular difference in best-corrected visual acuity
  4. * Near point of accommodation \> 20 cm in either eye as measured by push-up method
  5. * Manifest or latent nystagmus
  6. * Non-strabismic binocular vision and accommodative disorders associated with known disease of the brain
  7. * Diseases known to affect accommodation, vergence, or ocular motility such as multiple sclerosis, Graves orbitopathy, myasthenia gravis, diabetes mellitus, Parkinson disease
  8. * Any ocular or systemic medication known to affect accommodation or vergence such as anti-anxiety agents (e.g., Librium or Valium), anti-arrhythmic agents (e.g., Cifenline, Cibenzoline), anti-cholinergics, bladder spasmolytic drugs (e.g., Propiverine), hydroxychloroquine, chloroquine, phenothiazines (e.g., Compazine, Mellaril, Thorazine), tricyclic antidepressants (e.g., Elavil, Nortriptyline, Tofranil)
  9. * Inability to comprehend and/or perform any study-related test or procedure

Contacts and Locations

Study Contact

Chang Yaramothu, PhD
CONTACT
9735585456
cto@omtvr.com

Principal Investigator

Chang Yaramothu, PhD
STUDY_CHAIR
OculoMotor Technologies
Tara L Alvarez, PhD
PRINCIPAL_INVESTIGATOR
OculoMotor Technologies
Mitchell M Scheiman, OD, PhD
PRINCIPAL_INVESTIGATOR
OculoMotor Technologies

Study Locations (Sites)

OculoMotor Technologies
Newark, New Jersey, 07103
United States
The Eye Institute at Salus University
Philadelphia, Pennsylvania, 19141
United States

Collaborators and Investigators

Sponsor: OculoMotor Technologies

  • Chang Yaramothu, PhD, STUDY_CHAIR, OculoMotor Technologies
  • Tara L Alvarez, PhD, PRINCIPAL_INVESTIGATOR, OculoMotor Technologies
  • Mitchell M Scheiman, OD, PhD, PRINCIPAL_INVESTIGATOR, OculoMotor Technologies

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2021-10-14
Study Completion Date2024-09

Study Record Updates

Study Start Date2021-10-14
Study Completion Date2024-09

Terms related to this study

Additional Relevant MeSH Terms

  • Convergence Insufficiency